ACTG

Acacia Research Corp. 10-K Summary (Fiscal Year Ended Dec 31, 2003)

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2003, for Acacia Research Corporation. The company operates two distinct business groups, each with its own class of common stock: the CombiMatrix Group (life sciences technology, semiconductor-based arrays) and the Acacia Technologies Group (intellectual property licensing, specifically Digital Media Transmission and V-chip technologies). The company is headquartered in Newport Beach, California.

Key Financial Metrics

Note: The company reported no long-term indebtedness as of December 31, 2003. Working capital includes significant deferred revenue liabilities ($18.1 million current, $3.9 million non-current) primarily from the CombiMatrix group.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 30% to $1.148 million, driven by the Acacia Technologies group beginning to recognize Digital Media Transmission (DMT) license fee revenues ($692,000) and CombiMatrix product sales ($407,000). In 2002, revenue was heavily reliant on one-time V-chip settlements.
• Reduced Net Loss: The net loss narrowed significantly to $24.4 million from $59.0 million in 2002. This improvement is largely due to the absence of large one-time charges in 2003 that occurred in 2002, specifically a $17.2 million charge for acquired in-process research and development (IPR&D) and an $18.5 million legal settlement charge related to the CombiMatrix group.
• Operating Expenses: Total operating expenses decreased to $26.5 million from $81.2 million, reflecting the removal of the aforementioned non-recurring charges and a reduction in research and development expenses for CombiMatrix ($8.1 million in 2003 vs. $18.2 million in 2002).
• Capital Structure: In May 2003, the company raised $4.9 million in net proceeds through a private equity financing attributed to the CombiMatrix group.

Guidance, Outlook, and Risks

Management Commentary: Management expects to incur significant losses for the foreseeable future as both groups continue to invest in research and development and commercialization. The company does not anticipate paying cash dividends in the foreseeable future.

Outlook:

• CombiMatrix: Focused on commercializing its array platform. In November 2003, Roche announced it would not launch its array platform in 2003 as previously indicated. CombiMatrix responded by launching its own "CustomArray" platform to beta customers in December 2003. The group received $9.8 million in milestone payments from Roche in 2003, recorded as deferred revenue.
• Acacia Technologies: The V-chip patent expired in July 2003, ending a major revenue stream. The group is pivoting to commercialize its DMT technology, having executed 108 license agreements in 2003. Future revenue is uncertain and dependent on licensee sales.

Risks and Contingencies:

• Litigation: Pending appeals regarding V-chip patent infringement (Soundview Technologies) and active DMT patent infringement lawsuits against adult entertainment providers and On Command Corporation. Outcomes are uncertain.
• Liquidity: While cash balances ($50.5 million including short-term investments) are sufficient for the next 12 months, the company has a history of losses and may require additional financing.
• Technology Risk: CombiMatrix relies on unproven technology and strategic partnerships (e.g., Roche, Toppan). Failure to commercialize or secure new partners could be fatal to the business.

Investor Verification Checklist

• Deferred Revenue Recognition: Verify the timeline for recognizing the $22 million in deferred revenue (primarily from Roche and Toppan) and the specific milestones required to release these funds.
• DMT Licensing Viability: Assess the collectibility and recurring nature of the $692,000 in DMT license fees, given the expiration of the V-chip patent and the reliance on third-party licensee sales.
• Legal Exposure: Monitor the status of the V-chip appeal and the DMT infringement lawsuits, as adverse rulings could impact future revenue streams or result in significant legal costs.
• CombiMatrix Commercialization: Confirm the progress of the "CustomArray" launch and the status of the partnership with Roche following the delay in their joint platform launch.
• Cash Burn Rate: Analyze the sustainability of the current cash position ($31.9 million cash + $18.6 million investments) against the projected operating losses and R&D spend.